Medical Therapy of Uveitic Macular Edema: Biologic Agents

Aleksandra Radosavljevic, Mamta Agarwal, Bahram Bodaghi, Justine R. Smith, Manfred Zierhut

Research output: Contribution to journalReview article


Introduction: Uveitic macular edema (UME) is a significant cause of visual impairment in all uveitis types. Methods: Reports that were cited in the MEDLINE database, that analyzed the effectiveness of biologics for UME in at least five patients, with a minimum follow-up of 3 months, published prior to April 1, 2019 were included. Reports that did not compare UME findings before and after the therapy, using either OCT or fluorescein angiography, were excluded. Results: Case series that analyzed the efficacy of intravitreal anti-VEGF agents showed modest, short-term benefit. Studies that investigated systemic anti-TNF agents in patients with noninfectious uveitis reported a therapeutic effect on UME. Anti-IL-6 antibodies have shown promising results for most severe cases of noninfectious UME. Interferon represents an option for patients with persistent UME in infectious and noninfectious uveitis. Conclusion: Multicenter, randomized controlled trials are needed to assess the effectiveness of each group of biologic agents in sufficient number of patients.

Original languageEnglish
Number of pages12
JournalOcular Immunology and Inflammation
Publication statusE-pub ahead of print - 14 Feb 2020


  • biologic agents
  • interferon
  • interleukin 6 inhibitor
  • macular edema
  • medical therapy
  • tumor necrosis factor inhibitors
  • Uveitis
  • vascular endothelial growth factor

Fingerprint Dive into the research topics of 'Medical Therapy of Uveitic Macular Edema: Biologic Agents'. Together they form a unique fingerprint.

  • Cite this